211 related articles for article (PubMed ID: 20686120)
41. West nile virus-induced activation of mammalian target of rapamycin complex 1 supports viral growth and viral protein expression.
Shives KD; Beatman EL; Chamanian M; O'Brien C; Hobson-Peters J; Beckham JD
J Virol; 2014 Aug; 88(16):9458-71. PubMed ID: 24920798
[TBL] [Abstract][Full Text] [Related]
42. Targeting aurora kinases as therapy in multiple myeloma.
Shi Y; Reiman T; Li W; Maxwell CA; Sen S; Pilarski L; Daniels TR; Penichet ML; Feldman R; Lichtenstein A
Blood; 2007 May; 109(9):3915-21. PubMed ID: 17213289
[TBL] [Abstract][Full Text] [Related]
43. TORC2 Structure and Function.
Gaubitz C; Prouteau M; Kusmider B; Loewith R
Trends Biochem Sci; 2016 Jun; 41(6):532-545. PubMed ID: 27161823
[TBL] [Abstract][Full Text] [Related]
44. Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells.
Zeng Q; Qin S; Zhang H; Liu B; Qin J; Wang X; Zhang R; Liu C; Dong X; Zhang S; Huang S; Chen L
J Cell Physiol; 2018 Jan; 233(1):516-529. PubMed ID: 28300280
[TBL] [Abstract][Full Text] [Related]
45. The antileukemia roles of PP242 alone or in combination with daunorubicin in acute leukemia.
Shi F; Yang X; Gong Y; Shi R; Yang X; Naren D; Wu J
Anticancer Drugs; 2015 Apr; 26(4):410-21. PubMed ID: 25535978
[TBL] [Abstract][Full Text] [Related]
46. Dysregulation of epithelial Na+ absorption induced by inhibition of the kinases TORC1 and TORC2.
Mansley MK; Wilson SM
Br J Pharmacol; 2010 Dec; 161(8):1778-92. PubMed ID: 20735411
[TBL] [Abstract][Full Text] [Related]
47. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation.
Wang X; Yue P; Kim YA; Fu H; Khuri FR; Sun SY
Cancer Res; 2008 Sep; 68(18):7409-18. PubMed ID: 18794129
[TBL] [Abstract][Full Text] [Related]
48. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.
Görgün G; Calabrese E; Hideshima T; Ecsedy J; Perrone G; Mani M; Ikeda H; Bianchi G; Hu Y; Cirstea D; Santo L; Tai YT; Nahar S; Zheng M; Bandi M; Carrasco RD; Raje N; Munshi N; Richardson P; Anderson KC
Blood; 2010 Jun; 115(25):5202-13. PubMed ID: 20382844
[TBL] [Abstract][Full Text] [Related]
49. LST8 regulates cell growth via target-of-rapamycin complex 2 (TORC2).
Wang T; Blumhagen R; Lao U; Kuo Y; Edgar BA
Mol Cell Biol; 2012 Jun; 32(12):2203-13. PubMed ID: 22493059
[TBL] [Abstract][Full Text] [Related]
50. The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT.
David E; Sun SY; Waller EK; Chen J; Khuri FR; Lonial S
Blood; 2005 Dec; 106(13):4322-9. PubMed ID: 16118318
[TBL] [Abstract][Full Text] [Related]
51. Comparative effects of PP242 and rapamycin on mTOR signalling and NOTCH signalling in leukemia cells.
Ono A; Oike R; Okuhashi Y; Takahashi Y; Itoh M; Nara N; Tohda S
Anticancer Res; 2013 Mar; 33(3):809-13. PubMed ID: 23482748
[TBL] [Abstract][Full Text] [Related]
52. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
53. Dual mTOR/PI3K inhibitor NVP‑BEZ235 arrests colorectal cancer cell growth and displays differential inhibition of 4E‑BP1.
Alqurashi N; Hashimi SM; Alowaidi F; Ivanovski S; Wei MQ
Oncol Rep; 2018 Aug; 40(2):1083-1092. PubMed ID: 29845289
[TBL] [Abstract][Full Text] [Related]
54. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
Zhang X; Wang X; Xu T; Zhong S; Shen Z
Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
[TBL] [Abstract][Full Text] [Related]
55. A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
Powles T; Wheater M; Din O; Geldart T; Boleti E; Stockdale A; Sundar S; Robinson A; Ahmed I; Wimalasingham A; Burke W; Sarker SJ; Hussain S; Ralph C
Eur Urol; 2016 Mar; 69(3):450-6. PubMed ID: 26364551
[TBL] [Abstract][Full Text] [Related]
56. PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis.
Thedieck K; Polak P; Kim ML; Molle KD; Cohen A; Jenö P; Arrieumerlou C; Hall MN
PLoS One; 2007 Nov; 2(11):e1217. PubMed ID: 18030348
[TBL] [Abstract][Full Text] [Related]
57. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1).
García-Martínez JM; Alessi DR
Biochem J; 2008 Dec; 416(3):375-85. PubMed ID: 18925875
[TBL] [Abstract][Full Text] [Related]
58. Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma.
Liu TT; Yang KX; Yu J; Cao YY; Ren JS; Hao JJ; Pan BQ; Ma S; Yang LY; Cai Y; Wang MR; Zhang Y
J Mol Med (Berl); 2018 Aug; 96(8):807-817. PubMed ID: 29959473
[TBL] [Abstract][Full Text] [Related]
59. Torin2 Potentiates Anticancer Effects on Adult T-Cell Leukemia/Lymphoma by Inhibiting Mammalian Target of Rapamycin.
Watanabe T; Sato A; Kobayashi-Watanabe N; Sueoka-Aragane N; Kimura S; Sueoka E
Anticancer Res; 2016 Jan; 36(1):95-102. PubMed ID: 26722032
[TBL] [Abstract][Full Text] [Related]
60. The mTOR Kinase Inhibitor CZ415 Inhibits Human Papillary Thyroid Carcinoma Cell Growth.
Li X; Li Z; Song Y; Liu W; Liu Z
Cell Physiol Biochem; 2018; 46(2):579-590. PubMed ID: 29617677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
